(RS)-4-Carboxyphenylglycine

CAS No. 7292-81-1

(RS)-4-Carboxyphenylglycine( —— )

Catalog No. M33915 CAS No. 7292-81-1

(RS)-4-Carboxyphenylglycine is a racemic mixture. (S)-4-Carboxyphenylglycine is a selective mGlu1α receptor antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 31 In Stock
10MG 48 In Stock
25MG 79 In Stock
50MG 116 In Stock
100MG 169 In Stock
200MG Get Quote In Stock
500MG 402 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (RS)-4-Carboxyphenylglycine
  • Note
    Research use only, not for human use.
  • Brief Description
    (RS)-4-Carboxyphenylglycine is a racemic mixture. (S)-4-Carboxyphenylglycine is a selective mGlu1α receptor antagonist.
  • Description
    (RS)-4-Carboxyphenylglycine is a racemic mixture. (S)-4-Carboxyphenylglycine is a selective mGlu1α receptor antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    7292-81-1
  • Formula Weight
    195.17
  • Molecular Formula
    C9H9NO4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(O)=O)(N)C1=CC=C(C(O)=O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • α-Conotoxin IMI

    α-Conotoxin Im-I is a selective α7/α9 nAChR antagonist, blocking α7 nicotinic receptors with the highest apparent affinity, while having an 8-fold lower affinity for homomeric α9 nicotinic receptors. α-Conotoxin Im-I is toxic and induces seizures in rodents. α-Conotoxin Im-I is a tool for studying neuronal nAChR.

  • Filorexant

    Filorexant is an orally bioavailable effective and selective reversible antagonist of OX1 and OX2 receptor with (Ki <3 nM).

  • 8-Hydroxyguanosine

    8-hydroxyguanosine (8-OHG) is a marker for measuring the rate of oxidative damage to nucleic acids and lipids.The concentration of 8-OHG in CSF in Parkinson's disease (PD) patients is approximately three-fold that in controls. The concentration of 8-OHG in CSF decreased significantly with the duration of disease. However, the concentration of 8-OHG in serum was not significantly altered in PD patients compared to that in controls.